 I-Mab NASDAQ: IMAB unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AGs OTC: RHHBY Tecentriq atezolizumab in patients with advanced cancer. An abstract detailing data from the trial will be presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, taking place next month. 